Apis Capital Advisors LLC boosted its stake in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 21.4% during the third quarter, Holdings Channel.com reports. The fund owned 102,000 shares of the technology company’s stock after purchasing an additional 18,000 shares during the quarter. Opiant Pharmaceuticals comprises 2.5% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 18th biggest position. Apis Capital Advisors LLC’s holdings in Opiant Pharmaceuticals were worth $2,625,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC acquired a new stake in Opiant Pharmaceuticals in the 3rd quarter valued at $772,000. Geode Capital Management LLC grew its stake in Opiant Pharmaceuticals by 290.0% in the 3rd quarter. Geode Capital Management LLC now owns 50,244 shares of the technology company’s stock valued at $1,293,000 after acquiring an additional 37,362 shares during the period. EAM Investors LLC acquired a new stake in Opiant Pharmaceuticals in the 3rd quarter valued at $1,777,000. Essex Investment Management Co. LLC acquired a new stake in Opiant Pharmaceuticals in the 3rd quarter valued at $638,000. Finally, BlackRock Inc. boosted its stake in Opiant Pharmaceuticals by 107.2% during the 3rd quarter. BlackRock Inc. now owns 24,686 shares of the technology company’s stock worth $635,000 after purchasing an additional 12,774 shares during the last quarter. 26.90% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Oppenheimer began coverage on shares of Opiant Pharmaceuticals in a research note on Wednesday, December 8th. They set an “outperform” rating and a $42.00 target price on the stock.
In other news, insider Phil Skolnick sold 1,518 shares of Opiant Pharmaceuticals stock in a transaction on Thursday, January 27th. The stock was sold at an average price of $26.19, for a total transaction of $39,756.42. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Roger Crystal sold 1,058 shares of the business’s stock in a transaction dated Monday, January 10th. The shares were sold at an average price of $30.49, for a total transaction of $32,258.42. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,388 shares of company stock worth $149,142. Insiders own 28.56% of the company’s stock.
Shares of OPNT opened at $24.33 on Monday. Opiant Pharmaceuticals, Inc. has a 52-week low of $10.00 and a 52-week high of $37.71. The company has a quick ratio of 9.23, a current ratio of 9.23 and a debt-to-equity ratio of 0.45. The firm’s fifty day moving average is $30.17 and its two-hundred day moving average is $24.16. The stock has a market cap of $114.84 million, a PE ratio of 486.70 and a beta of 0.50.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Thursday, November 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.41. Opiant Pharmaceuticals had a net margin of 3.58% and a return on equity of 4.25%. The company had revenue of $16.34 million for the quarter, compared to analysts’ expectations of $12.45 million. During the same quarter in the previous year, the company posted $0.15 EPS. As a group, research analysts anticipate that Opiant Pharmaceuticals, Inc. will post 0.39 earnings per share for the current year.
Opiant Pharmaceuticals Profile
Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.
Read More: What is a back-end load?
Want to see what other hedge funds are holding OPNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT).
Want More Great Investing Ideas?